Sign in
CompletedNo phase

Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder

Key facts

Who runs it
Trustees of Dartmouth College
Where
Albuquerque, Nashua, Salt Lake City, and Tacoma, United StatesSee the 4 sites
Trial code
Status
Completed
People taking part
149 people enrolled
Started
18 Aug 2022
Ended
5 Feb 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
Record updated
25 February 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Site Staff
  • 18 years of age and older
  • Employed at the clinic as an identified stakeholder role (provider, pharmacist, pharmacy technician, or administrator); Patients
  • 18 years of age or older
  • A patient of the participating clinic who is receiving or has received MOUD from a provider employed by the clinic
  • Exposed to the PrIMO model at the clinic site for at least 14 days

Who cannot take part

  • Site Staff
  • Unwilling or unable to provide consent
  • Are currently in jail, prison, or other overnight facility as required by court of law; or have pending legal action that could prevent participation in study activities; Patients
  • Not able to speak English sufficiently to understand study procedures and provide written informed consent
  • Unable or unwilling to provide consent or to participate in study procedures
  • Are currently in jail, prison, or other overnight facility as required by court of law; or have pending legal action that could prevent participation in study activities

Where in United States

  • UNM Truman Health ServicesAlbuquerque, United States
  • Harbor Health CareNashua, United States
  • Sugar House Health CenterSalt Lake City, United States
  • Community Health CareTacoma, United States

About the trial

What the trial wants to find out

This project will provide novel empirical information about how to optimally engage pharmacists and pharmacies as key partners in collaborative integrated care models designed to expand access to evidence-based medication treatment for OUD which may inform a larger experimental design that seeks to evaluate best ways to scale-up this model across the nation. This Phase 1 project seeks to evaluate the feasibility, acceptability, and impact of implementing a pharmacist-integrated model of MOUD into approximately four diverse outpatient clinical sites.

The 2 groups in the trial

  • Site StaffOther group

    Providers, Pharmacists, Pharmacy Technicians, Administrators to receive survey assessments

    Treatment: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)

  • PatientsOther group

    Subset of patients receiving PrIMO care to receive survey assessments

    Treatment: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
25 February 2025